Investigating Bone and Metabolic Outcomes in Postmenopausal Women: OASIS-3 Results

An expert discusses how menopause triggers increased bone remodeling with imbalanced resorption exceeding formation, leading to progressive bone loss and potential osteoporosis that requires careful attention to optimize bone health.

An expert discusses how estrogen remains the most effective treatment for vasomotor symptoms while also benefiting bone density, though alternative treatments like paroxetine and fezolinetant lack bone health benefits.

An expert discusses how neurokinin receptor antagonists like fezolinetant (NK3) and elinzanetant (NK1/NK3) work in the hypothalamus to reduce vasomotor symptoms, with elinzanetant showing promising skeletal benefits.

An expert discusses how the OASIS-3 trial was designed as a 52-week placebo-controlled study in postmenopausal women with moderate to severe vasomotor symptoms, including experimental bone health end points.

An expert discusses how elinzanetant showed less bone mineral density decrease, reduced bone turnover markers, and increased total body bone density compared to placebo, suggesting beneficial skeletal effects.

An expert discusses how elinzanetant demonstrated favorable body composition changes including weight loss, decreased fat mass index, and increased lean mass index in postmenopausal women.

An expert discusses how the OASIS-3 subanalysis provides intriguing evidence for potential long-term bone health benefits from elinzanetant alongside vasomotor symptom treatment, warranting further research.

An expert discusses how fezolinetant appears to have neutral effects on bone density and bone health based on current 52-week study data in postmenopausal women.

An expert discusses how pooled clinical trial data shows fezolinetant does not cause weight gain or body mass index changes, though specific weight and muscle mass studies are not yet published

An expert discusses how the ideal vasomotor symptom treatment would address both symptoms and bone loss simultaneously, making nonestrogen therapies with skeletal benefits like elinzanetant particularly attractive for patients.